Suchergebnisse - "Hypomethylating agent"

Effect of the reverse transcriptase inhibitor efavirenz on 5-azacytidine-induced LINE1 long interspersed repeat expression and genetic instability in acute myeloid leukemia cells

Autoren: Kh. M. Magomedova I. A. Antonova M. S. Strelkov et al.

Quelle: Успехи молекулярной онкологии, Vol 12, Iss 2, Pp 89-103 (2025)

Schlagwörter: retroviral reverse transcriptase inhibitor, hypomethylating agent, 5-azacytidine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, efavirenz, acute myeloid leukemia, long interspersed repeats line1, RC254-282

Zugangs-URL: https://doaj.org/article/313432172e3549cdb215512368d2707e

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.

Autoren: Cortes, Jorge Roboz, Gail Baer, Maria et al.

Quelle: Journal of Hematology & Oncology. 18(1)

Schlagwörter: AML, Combination therapy, Hypomethylating agent, Isocitrate dehydrogenase-1, Mutant IDH1 inhibitor, Refractory, Relapsed, Humans, Azacitidine, Male, Middle Aged, Aged, Female, Leukemia, Myeloid, Acute, Adult, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Remission Induction, Isocitrate Dehydrogenase, Pyridines

Dateibeschreibung: application/pdf

Zugangs-URL: https://escholarship.org/uc/item/5dt931b4
https://escholarship.org/content/qt5dt931b4/qt5dt931b4.pdf

BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia

Autoren: Weijia Zang Yui Koike Koutarou Nishimura et al.

Quelle: Scientific Reports, Vol 15, Iss 1, Pp 1-15 (2025)

Schlagwörter: Acute myeloid leukemia, EVI1, Venetoclax, Hypomethylating agent, MYB, BRD4, Medicine, Science

Dateibeschreibung: electronic resource

Relation: https://doaj.org/toc/2045-2322

Zugangs-URL: https://doaj.org/article/e465d6b167654bb79eb4908c7e847320

Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review

Autoren: Ruihua Mi Shuli Guo Weidong Yang et al.

Quelle: Frontiers in Oncology, Vol 15 (2025)

Schlagwörter: mixed-phenotype acute leukemia, venetoclax, hypomethylating agent, treatment, literature review, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Dateibeschreibung: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2025.1693061/full; https://doaj.org/toc/2234-943X

Zugangs-URL: https://doaj.org/article/f6ac6cb301654a8ca174113892861d83

RIG‐I‐Inducing Small Molecules Potently Inhibit HMA‐Resistant AML Through Igniting the Overloaded dsRNA Arsenal

Autoren: Xueqin Chen Jiaqi Wu Yuntong Li et al.

Quelle: Advanced Science, Vol 12, Iss 36, Pp n/a-n/a (2025)

Schlagwörter: anticancer immune response, acute myeloid leukemia, hypomethylating agent, interferon, RIG‐I, Science

Dateibeschreibung: electronic resource

Relation: https://doaj.org/toc/2198-3844

Zugangs-URL: https://doaj.org/article/172d23d484e546108dc37fc7d2373573

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia

Autoren: Othman, Tamer A Tenold, Matthew E Moskoff, Benjamin N et al.

Quelle: Expert Review of Hematology. 14(5)

Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3211 Oncology and Carcinogenesis (for-2020), Cancer (rcdc), Hematology (rcdc), Childhood Leukemia (rcdc), Pediatric (rcdc), Pediatric Cancer (rcdc), Clinical Research (rcdc), Rare Diseases (rcdc), 6.1 Pharmaceuticals (hrcs-rac), Cancer (hrcs-hc), 3 Good Health and Well Being (sdg), Antineoplastic Combined Chemotherapy Protocols (mesh), Azacitidine (mesh), Bridged Bicyclo Compounds, Heterocyclic (mesh), Cytarabine (mesh), Decitabine (mesh), Humans (mesh), Leukemia, Myeloid, Acute (mesh), Sulfonamides (mesh), Acute myeloid leukemia, aml, azacitidine, cytarabine, decitabine, hma, hypomethylating agent, ldac, venetoclax, Humans (mesh), Sulfonamides (mesh), Azacitidine (mesh), Cytarabine (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Leukemia, Myeloid, Acute (mesh), Bridged Bicyclo Compounds, Heterocyclic (mesh), Decitabine (mesh), Acute myeloid leukemia, aml, azacitidine, cytarabine, decitabine, hma, hypomethylating agent, ldac, venetoclax, Antineoplastic Combined Chemotherapy Protocols (mesh), Azacitidine (mesh), Bridged Bicyclo Compounds, Heterocyclic (mesh), Cytarabine (mesh), Decitabine (mesh), Humans (mesh), Leukemia, Myeloid, Acute (mesh), Sulfonamides (mesh), 1102 Cardiorespiratory Medicine and Haematology (for), 1199 Other Medical and Health Sciences (for), 3201 Cardiovascular medicine and haematology (for-2020)

Dateibeschreibung: application/pdf

Zugangs-URL: https://escholarship.org/uc/item/9r70j56g
https://escholarship.org/content/qt9r70j56g/qt9r70j56g.pdf

Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country

Autoren: Quang Hao Nguyen Minh Phuong Vu Ha Trang Kieu et al.

Quelle: Leukemia Research Reports, Vol 23, Iss , Pp 100490- (2025)

Schlagwörter: Myelodysplastic neoplasms, MDS, Erythropoiesis stimulating agent, Hypomethylating agent, Decitabine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Dateibeschreibung: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2213048924000803; https://doaj.org/toc/2213-0489

Zugangs-URL: https://doaj.org/article/f695be65219a4ae095ef15dab7479681

A Century of Hypomethylating Agent: A Remarkable Response to Azacitidine Monotherapy for Relapsed Acute Myeloid Leukemia - A Case Report

Autoren: Jeurkar, Chetan Majeed, Amry Wilde, Lindsay et al.

Quelle: Department of Medical Oncology Faculty Papers

Schlagwörter: acute myeloid leukemia, hypomethylating agent, inversion 16, palliative treatment, Hematology, Medicine and Health Sciences, Oncology

Dateibeschreibung: application/pdf

Relation: https://jdc.jefferson.edu/medoncfp/302; https://jdc.jefferson.edu/context/medoncfp/article/1302/viewcontent/000545569.pdf

Verfügbarkeit: https://jdc.jefferson.edu/medoncfp/302
https://jdc.jefferson.edu/context/medoncfp/article/1302/viewcontent/000545569.pdf

Clinical Presentation and Outcomes of Patients with Myelodysplastic syndrome

Autoren: Qudratullah Momina Javed Hira Tariq et al.

Quelle: Journal of Haematology and Stem Cell Research; Vol. 5 No. 1 (2025): January-June; 70-76 ; 2790-2285 ; 2790-2277

Schlagwörter: Myelodysplastic syndrome, Hypomethylating agent, Hemopoietic stem cells transplant

Dateibeschreibung: application/pdf

Relation: https://jhscr.org/index.php/JHSCR/article/view/203/173; https://jhscr.org/index.php/JHSCR/article/view/203

Verfügbarkeit: https://jhscr.org/index.php/JHSCR/article/view/203

Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response

Autoren: Apostolova, Petya Kreutmair, Stefanie Toffalori, Cristina et al.

Weitere Verfasser: Apostolova, Petya Kreutmair, Stefanie Toffalori, Cristina et al.

Quelle: British journal of haematology, vol. 203, no. 2, pp. 264-281

Schlagwörter: AML, HCT, acute myeloid leukaemia, allogeneic haematopoietic cell transplantation, hypomethylating agent, immune checkpoint inhibition, immune phenotype, relapse, single-cell RNA-sequencing, single-cell immunomonitoring, 2720 Hematology, HMA, 570 Life sciences, biology, 610 Medicine & health, Hematology, 10263 Institute of Experimental Immunology, 3. Good health

Dateibeschreibung: application/pdf; Phase_II_trial_of_hypomethylating_agent_combined_with_nivolumab.pdf - application/pdf; pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37539479
https://serval.unil.ch/notice/serval:BIB_34E444E517E5
https://serval.unil.ch/resource/serval:BIB_34E444E517E5.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_34E444E517E52
http://hdl.handle.net/11336/241849

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

Autoren: Josephine Lucero Salman Al-Harbi Karen W. L. Yee

Quelle: Curr Oncol
Current Oncology, Vol 30, Iss 7, Pp 6177-6196 (2023)

Schlagwörter: Risk, prognostic scoring system, hypomethylating agent, lenalidomide, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Review, Prognosis, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, antithymocyte globulin, Myelodysplastic Syndromes, Neoplasms, Humans, Immunologic Factors, myelodysplastic neoplasm, Lenalidomide, luspatercept, RC254-282

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37504319
https://doaj.org/article/1b715c1349b94bfd90324ecd0f55f5af

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

Autoren: Hui Liu Hao Jiang Hongyan Tong et al.

Quelle: Cancer Med
Cancer Medicine, Vol 12, Iss 13, Pp 13885-13893 (2023)

Schlagwörter: Adult, Neutropenia, hypomethylating agent, complete remission, overall survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Decitabine, myelodysplastic syndromes, 3. Good health, RESEARCH ARTICLE, Treatment Outcome, Myelodysplastic Syndromes, Azacitidine, Humans, decitabine, RC254-282

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37350499
https://doaj.org/article/50a8af396c0a41e28fc1444429af2f12

Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach

Autoren: Aditi Sharma Danielle Blake Jay Yang

Quelle: Hemato, Vol 6, Iss 2, p 16 (2025)

Schlagwörter: AML, acute myeloid leukemia, Jehovah’s Witness, venetoclax, hypomethylating agent, azacitidine, Medicine

Dateibeschreibung: electronic resource

Relation: https://www.mdpi.com/2673-6357/6/2/16; https://doaj.org/toc/2673-6357

Zugangs-URL: https://doaj.org/article/1eb7f41f4d484e6fb768669cd45ea175

Multi-Organ Adverse Reaction to Two Hypomethylating Agents: A Challenge in High-Risk Myelodysplastic Syndrome Treatment

Autoren: Sofia Brites Alves Francesca Pierdomenico

Quelle: Hematology Reports, Vol 17, Iss 3, p 29 (2025)

Schlagwörter: myelodysplastic syndrome, hypomethylating agent, azacitidine, decitabine, hypersensitivity, hemato-oncological patients, Diseases of the blood and blood-forming organs, RC633-647.5

Dateibeschreibung: electronic resource

Relation: https://www.mdpi.com/2038-8330/17/3/29; https://doaj.org/toc/2038-8330

Zugangs-URL: https://doaj.org/article/c6309092c2a54314b25cd55114ca242b

Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment

Autoren: Xiaoning Wang Jiashuo Guo Yan Liu et al.

Quelle: Front Med (Lausanne)
Frontiers in Medicine, Vol 11 (2024)

Schlagwörter: azacitidine, Medicine (General), 03 medical and health sciences, R5-920, 0302 clinical medicine, venetoclax, hypomethylating agent, BCL2 inhibitor, blastic plasmacytoid dendritic cell neoplasm, Medicine, combination therapy, 3. Good health

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39086951
https://doaj.org/article/be087bedc3194c63bc7040d33a80f6fd

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Autoren: Tenold, Matthew E Moskoff, Benjamin N Benjamin, David J et al.

Schlagwörter: Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Pediatric Cancer, Childhood Leukemia, Pediatric, Clinical Research, Cancer, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, acute myeloid leukemia, venetoclax, hypomethylating agent, relapsed, refractory, real-world data, relapsed/refractory, Clinical sciences, Oncology and carcinogenesis

Dateibeschreibung: application/pdf

Zugangs-URL: https://escholarship.org/uc/item/6g52c8jt
https://escholarship.org/content/qt6g52c8jt/qt6g52c8jt.pdf

Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

Autoren: Maria Fortunata Lofiego Francesca Piazzini Francesca Pia Caruso et al.

Quelle: Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)

Schlagwörter: Glioblastoma, Brain metastases, Immunotherapy, DNA hypomethylating agent, Melanoma, Medicine

Dateibeschreibung: electronic resource

Relation: https://doaj.org/toc/1479-5876

Zugangs-URL: https://doaj.org/article/de9304cb7f1e45d7b01e1059c5afd11b

Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia

Autoren: Shuya Feng Yigang Yuan Zihan Lin et al.

Quelle: Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2024)

Schlagwörter: Ferroptosis, Glutathione peroxidase-4, AMPK, Acute myeloid leukemia, Hypomethylating agent, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Dateibeschreibung: electronic resource

Relation: https://doaj.org/toc/2162-3619

Zugangs-URL: https://doaj.org/article/84b5eef75bfa4328af9bf045a1b26690

Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report

Autoren: Verna Cheung Fotios V. Michelis Hassan Sibai

Quelle: EJHaem
eJHaem, Vol 4, Iss 1, Pp 269-272 (2023)

Schlagwörter: 03 medical and health sciences, 0302 clinical medicine, hypomethylating agent, primary myelofibrosis, Diseases of the blood and blood-forming organs, Case Reports, RC633-647.5, allogenic stem cell transplant, myeloid lineage chimerism, 3. Good health

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36819176
https://doaj.org/article/48dac9ddf0794a52b5d7b765694ea41b

MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia

Autoren: Yue Wei Hong Zheng Pamela Pennington Lockyer et al.

Quelle: Leukemia & Lymphoma. 63:3154-3164

Schlagwörter: 0301 basic medicine, Medical Sciences, Bioinformatics, chronic myelomonocytic leukemia, Myelodysplastic syndromes, Diseases, Biomedical Informatics, Mice, 03 medical and health sciences, MDM2, Hemic and Lymphatic Diseases, Medical Specialties, Medicine and Health Sciences, Animals, TP53, Chronic, 0303 health sciences, Leukemia, hypomethylating agent, Imidazoles, Leukemia, Myelomonocytic, Chronic, Myelomonocytic, Hematology, 3. Good health, Oncology, Myelodysplastic Syndromes, Azacitidine

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36059252